Hagedorn Research Institute granted multimillon sum for stem cell research  

The Hagedorn Research Institute, part of Novo Nordisk, has been granted DKK 120 mn for stem cell research from the EU and NIH

The Hagedorn Research Institute, part of healthcare company Novo Nordisk, has been granted DKK 120 mn (USD 19.2 mn) for stem cell research from EU research programmes and the National Institutes of Health, USA. The Hagedorn Research Institute will administer the money which will be used not only at the institute, but also in the extensive international network of which it forms a part.

Mads Krogsgaard Thomsen, research director at Novo Nordisk says that the efforts in stem cell research now can be assigned greater priority, and that the money has been granted because the institute has attracted very capable staff and conducted highly competent research.

Novo Nordisk's vision for the future is that stem cells can be used for cultivating insulin producing cells which then can be implanted in the pancreas to regulate the blood sugar. Mads Krogsgaard Thomsen does not see such a revolutionary breakthrough happening in the near future, but predicts that considerable steps towards it could have been taken in 15-20 years. Novo Nordisk holds the rights to commercialise a potential insulin treatment with stem cells. The news is reported by financial daily newspaper Børsen.

Link > The Hagedorn Research Institute 

Link > Novo Nordisk 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×